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1. Introduction 
Infectious agents have been implicated in the pathogenesis of many autoimmune diseases. 
In most of these diseases, including those in which specific organisms are known to play a 
role, the details of pathogenesis remain incompletely defined. Recent studies have aimed to 
isolate bacterial and viral pathogens from patients with autoimmune diseases, efforts have 
been made to further define the host immune response to infection, and there have been 
attempts to develop improved methods of diagnosis and treatment of infectious diseases 
affecting the Immune system. More recently, C.pneumonia has been linked to many 
autoimmune diseases [20]. 
Chlamydia pneumoniae is an important respiratory pathogen associated with 5% to 10% of 
community-acquired cases of pneumonia, pharyngitis, bronchitis, and sinusitis. Infection is 
most common among children 5 to 14 years of age, and the majority of adults have serologic 
evidence of past infection. Antibodies have also been found frequently in people in many 
countries worldwide. The bacterium is an obligatory intracellular pathogen that has the 
tendency to cause persistent infection, and may drive a chronic inflammatory reaction in 
coronary vasculature or other tissues. The characteristic feature of all chlamydial species is 
their tendency to establish a long-lasting parasitic relationship with the host and chronicity 
is a hallmark of Chlamydia infection. Adults are particularly prone to have prolonged illness, 
with relapses and secondary infections. Chlamydiae are known to infect macrophages and 
monocytes as well as epithelial cells. C. pneumoniae also infects endothelial and smooth 
muscle cells of blood vessels. Tissue injury in all chlamydial diseases appears to be immune 
mediated [27]. 
Only one serovar or immunotype has been found, Molecular studies have found only small 
and probably inconsequential differences among isolates. Despite its recent isolation, it 
should be said that C. pneumoniae is not a new organism. It was not found earlier because it 
is difficult to isolate and to keep in continuous culture. Retrospective serological studies 
provides evidence that C. pneumoniae was active for years before its isolation. Much of the 
knowledge of the epidemiology of C. pneumoniae infection has been derived from serologic 
studies utilizing the C. pneumoniae-specific microimmunofluorescence (MIF) test. More 
recent improvements in isolation techniques and the application of the PCR have also 
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greatly improved the capability to detect the organism in clinical specimens and facilitated 
more detailed microbiologic studies [40].  
This review is a brief discussion on recent studies about the association of C. pneumoniae 
infection with illnesses affecting the immune system, with an emphasis on the autoimmune 
diseases. 
2. Autoimmune disorders and infection 
2.1 Autoimmune diseases  
An autoimmune disorder is a condition that occurs when the immune system mistakenly 
attacks and destroys healthy body tissue. The immune system is an amazing collection of 
biological processes designed to defend the body against invasion by infectious pathogens 
and tumor cells. This system includes innate, adaptive and memory responses that are 
constantly activated, adapted and improved to meet the challenge of evading pathogens 
more efficiently. Normally the immune system's army of white blood cells helps protect the 
body from harmful substances, called antigens. Examples of antigens include bacteria, 
viruses, toxins, cancer cells, and blood or tissues from another person or species. In addition, 
the immune system must be tolerant and distinguish between self and nonself, so that 
substances that are identified as nonself stimulate an immune response, while no harm is 
inflicted upon self. However, as in any complex system, malfunctions occur, leading to 
diseases of immune dysregulation. In patients with an autoimmune disorder, the immune 
system can't tell the difference between healthy body tissue and antigens. The result is an 
immune response that destroys normal body tissues. This response is a hypersensitivity 
reaction similar to the response in allergies. In allergies, the immune system reacts to an 
external substance that it normally would ignore. With autoimmune disorders, the immune 
system reacts to normal body tissues. Furthermore autoimmunity is a consequence of the 
breakdown of self-tolerance; the result is an attack of the immune system on various organs 
and tissues as if they were foreign invaders [61].  
There are more than 80 different types of autoimmune disorders. Autoimmune diseases 
have many causes. Genes, notably genes encoding cell-surface proteins that display peptides 
for immune recognition, the major histocompatibility complex (MHC), the environment, 
and the microbial diversity within the human body determine the susceptibility to 
autoimmune diseases. One mechanism by which infection is linked to the initiation of 
autoimmunity is termed molecular mimicry. Molecular mimicry describes the phenomenon 
of protein products from dissimilar genes sharing similar structures that elicit an immune 
response to both self and microbial proteins. Auto immune diseases (ADs) are the third 
leading cause of morbidity and mortality, after heart disease and cancer, in the 
industrialized world. What causes the immune system to no longer tell the difference 
between healthy body tissues and antigens is not clearly known. Researchers are looking 
into the role of different factors in the development of autoimmune disorders. It seems that 
some microorganisms and drugs may trigger some of the changes, especially in people who 
have genes that make them more likely to get autoimmune disorders. One theory is that, a 
combination of genetic, immunologic, hormonal and environmental factors, comprising 
what is known as ‘the mosaic of autoimmunity’, is required for autoimmune disorders to 
develop [59]. Among these key elements, the impact of infections on the development of 
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autoimmunity is substantial, and various mechanisms have been suggested to explain this 
relationship. In recent years, the compound interplay between infections and autoimmunity 
has been studied extensively [58, 59]. 
An autoimmune disorder may result in destruction of one or more types of body tissue, 
abnormal growth of an organ, or changes in organ function. Organs and tissues commonly 
affected by autoimmune disorders include red blood cells, blood vessels, connective tissues, 
endocrine glands such as the thyroid or pancreas, muscles, joints, and skin. 
Main human autoimmune disorders are Multiple sclerosis, Rheumatoid Arthritis, 
Scleroderma, and Neurologic autoimmune diseases. With the exception of multiple 
sclerosis, these diseases are rare. Autoimmune disorders affect people of all genders, races, 
and ages, but certain people have an increase risk of developing autoimmune disorders. 
Main risk factors for autoimmune disorders are Gender, Age, Ethnicity, Family history of 
autoimmune disorders, Exposure to environmental agents and previous infection. 
2.2 Autoimmune disorders induced by infection 
The high percentage of disease-discordant pairs of monozygotic twins demonstrates the 
central role of environmental factors in the etiology of autoimmune diseases. Efforts were 
first focused on the search for triggering factors. The study of animal models has clearly 
shown that infections may trigger autoimmune diseases, which can also determine its 
clinical manifestations. Most infectious agents, such as viruses, bacteria and parasites, can 
induce autoimmunity via different mechanisms. In many cases, it is not a single infection 
but rather the ‘burden of infections’ from childhood that is responsible for the induction of 
autoimmunity. The development of an autoimmune disease after infection tends to occur in 
genetically susceptible individuals. By contrast, some infections can protect individuals 
from specific autoimmune diseases [50]. 
The observation that infection can precipitate an autoimmune disease dates back more than 
a century. The first human autoimmune disease described, paroxysmal cold 
hemoglobinuria, was thought of as a late consequence of syphilis, and rheumatic fever is 
still associated with preceding streptococcal infection. 
Bacterial and viral infections are commonplace in a variety of autoimmune and chronic 
illnesses such as the chronic fatigue syndrome; fibromyalgia syndrome, Gulf war illnesses 
and rheumatoid conditions. Much attention is focused at present on the role of bacteria and 
the possible mechanisms of their involvement in the pathogenesis of several diseases. The 
route of infection and penetration, and the immune responses of the host can not only make 
any bacterial infection pathogenic but probably can also determine the aggressiveness of the 
disease and the chance for full recovery [21].  
A wide variety of bacterial infections have been associated with autoimmune disorders. For 
example M.pneumonia, M.salivarium, and M.fermentas, has been strongly associated with 
rheumatoid arthritis. Proteus mirabilis has been implicated in the pathogenesis of rheumatoid 
arthritis and osteoarthritis. Enterobacteriaceae family is associated with some autoimmune 
conditions such as Kawasaki syndrome and Graves disease. Genitourinary mycoplasma 
infection has been associated with systemic lupus erythematosus. Campylobacter jejuni, 
Haemophilus influenza and M. pneumoniae have been implicated as possible causative of 
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Guillain-Barre syndrome .Recently it has drawn attention to the putative link of bacterial 
nasopharyngeal infections with optic neuritis, optochiasmatic arachnoiditis and Multiple 
Sclerosis.  More recently serology and PCR(polymerase chain reaction) have provided 
ample evidence of Chlamydia pneumonia ,Borrelia burgdoferi, Mycoplasma species, human 
herpesvirus-1 and -6 among others in MS, Amyoyrophic Lateral Sclerosis, Alzheimer's and 
Parkinson's diseases. A tentative relationship between MS and streptococcal infection has 
been suggested. And finally acute rheumatic fever, which presents several weeks after 
infection with Streptococcus pyogenes in which, the Molecular resemblance between the 
bacterial M-protein and human glycoproteins results in a breakdown of self-tolerance in 
genetically susceptible individuals [24, 58]. 
Post-infection autoimmunity can be induced by multiple mechanisms, such as molecular 
mimicry, epitope spreading, bystander activation, viral persistence and polyclonal 
activation. The induction of a Guillain-Barré syndrome in rabbits after immunization with a 
peptide derived from Campylobacter jejuni is explained by mimicry between C. jejuni 
antigens and peripheral nerve axonal antigens. Triggering of autoimmunity is not always a 
hit and run event, but rather a cumulative process. The immune system is affected by 
repeated infections from childhood, and in immune-sensitive individuals, a breakthrough 
point might occur when the infection burden crosses a crucial level. This breakthrough point 
might be reached when a specific pathogen load, immune load (i.e. antibody titer) or a 
unique combination of pathogens is established [23]. 
Even though there are many tests available, the MIF test is the only currently acceptable 
serologic test for detection of C. pneumoniae antibodies and is widely accepted as the “gold 
standard” in C. pneumoniae Serodiagnonosis [18]. Serologic tests detect antibodies to a 
specific micro-organism, which indicates that infection with the micro-organism, took place 
at some point in time. However, absolute proof of the micro-organisms actual involvement 
in the process atherosclerosis could only come from demonstrating its presence in the 
vascular wall. 
3. Chlamydia pneumoniae and autoimmune diseases 
3.1 Multiple sclerosis  
Multiple sclerosis (MS) is an inflammatory disease leading to disseminated lesions of the 
central nervous system resulting in both somatomotor and autonomic disturbances. 
Somatomotor and autonomic disturbances occur with similar frequency. Multiple sclerosis 
is the most common demyelinating disease of the human central nervous system (CNS), 
principally affects adults aged 18–50 years. Women are generally affected earlier and more 
frequently than men. Most patients present with a relapsing disease, progressing over 10– 15 
years to a chronic phase with increasing difficulty in movement and co-ordination. 
The pathological hallmark of MS is the demyelinating plaque that represents an area of 
demyelination and gliosis around blood vessels. Acute lesions show perivascular 
lymphocytic infiltration with infiltration of macrophages and phagocytosis of myelin 
membranes. Underlying axons are relatively spared, but are nonetheless affected by the 
inflammatory process; leading to irreversible damage. Current opinion favors the notion 
that MS is an autoimmune disease directed against self-neural antigens [57]. 
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The disorder is most commonly diagnosed between ages 20 and 40, but can be seen at any 
age. It is caused by damage to the myelin sheath, the protective covering that surrounds 
nerve cells. When this nerve covering is damaged, nerve impulses are slowed down or 
stopped. The nerve damage is caused by inflammation. Inflammation occurs when the 
body's own immune cells attack the nervous system. Repeated episodes of inflammation 
can occur along any area of the brain, optic nerve, and spinal cord. People with a family 
history of MS and those who live in a geographical area where MS is more common have 
a slightly higher risk of the disease. The disease usually occurs sporadically and studies of 
identical twins in which one has MS have demonstrated that it occurs in only 30% of 
second twins [57]. 
Additional evidence for the role of infection in MS is provided by the presence of increased 
levels of IgG and the presence of oligoclonal bands with alkaline isoelectric points on 
electrophoresis gels. Oligoclonal bands occur in. 95% of MS patients, but are also seen in 
10% of patients with other infectious diseases of the CNS. This pattern of increased IgG and 
oligoclonal bands is found almost exclusively in CNS disorders of infectious origin and is 
thought to represent an intrathecal immune response to an infectious agent with the 
oligoclonal bands representing antibodies synthesized within the CNS [57]. The bacterium 
may act to trigger the autoimmune process because antigenic mimicry or from an expansion 
of self auto reactive T cell clones in response to bacterial or viral superantigens [58]. 
Chlamydia pneumoniae is the latest pathogen to be associated with MS. A case of CNS 
infection with C. pneumoniae in a patient with rapidly progressive MS has been reported. 
Antimicrobial therapy directed against this pathogen was accompanied by marked 
neurological improvement [60]. Subsequent studies found that C. pneumoniae is present in 
the CSF of patients with newly diagnosed relapsing, remitting MS and in patients with 
progressive MS, but not in other neurological disease controls [61]. 
Although there is a strong association between C. pneumoniae and MS, its role remains 
unproven. Before a causal relationship with the development or progression of MS can be 
claimed, the relapsing remitting nature of the disease that later develops into a chronic 
progressive phase must be explained satisfactorily. Moreover, the immune abnormalities in 
CSF (increased immunoglobulin synthesis and oligoclonal bands), the sex bias and the 
geographical distribution of the disease must all be addressed. One of the hallmarks of 
chlamydial infection is its tissue persistence and the development of chronic infection. 
Chlamydiae are known to infect macrophages and monocytes as well as epithelial cells. C. 
pneumoniae also infects endothelial and smooth muscle cells of blood vessels. Tissue injury in 
all chlamydial diseases appears to be immune mediated [66]. 
Recently, it has showed the specificity of intrathecal antibody response to C. pneumoniae 
antigens in relapsing remitting and progressive MS patients [74]. In most of MS patients 
studied, an elevated antibody titre to C. pneumoniae EB antigens was seen and was present in 
the CSF of them [74]. Increased antibody titres to C. pneumoniae were seen in about 20% of 
other neurological disease controls [24, 38]. 
Studies carried out by many researchers support a role for C. pneumoniae infection of the 
CNS in the pathogenesis of MS. However, the similarities in clinical disease pattern between 
known chlamydial diseases and MS do not conclusively establish a causal relationship 
between C. pneumoniae infection of the CNS and the development or progression of MS. 
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Further evidence to confirm or repudiate the presence of C. pneumoniae infection of the CNS 
in MS patients is needed. Evaluation of brain tissue from MS patients by immunochemical 
and in-situ PCR staining for C. pneumoniae is also necessary. If such studies show C. 
pneumoniae infection of microglial cells or oligodendrocytes in MS plaque or tissues adjacent 
to plaques, clinical neurologists can then consider treating MS patients with long term 
antimicrobial agents. The design of an appropriate therapeutic trial may be difficult because 
of the current absence of experimental animal models for either MS or for C. pneumoniae 
induced inflammation and demyelination of the CNS. Only a well designed therapeutic trial 
with sufficient statistical power is likely to provide additional answers concerning the 
relationship between C. pneumoniae infection of the CNS and the development or 
progression of MS [38]. 
As a large number of individuals are infected with the organism, it is possible that C. 
pneumoniae is the inciting agent of MS in genetically susceptible individuals. Activation of 
perivascular and parenchymal microglial cells along with the attendant biochemical 
mediators would lead to destruction of the surrounding myelin. An infectious agent that 
targeted microglial cells and endothelial cells would be a likely candidate in MS [49]. 
C. pneumoniae IgM positive cases were more frequent among the patients with rheumatoid 
arthritis , systemic lupus erythematosus, dermatomyositis/polymyositis , myeloperoxidase-
antineutrophil cytoplasmic autoantibody -associated vasculitis , adult onset of Still's disease 
and giant cell arteritis/Takayasu arteritis than among the controls [24]. 
3.2 Stroke, an immunopathogenic complication of persistent C. pneumonia illness 
Etiology of ischemic stroke is multi factorial and infections have emerged as one among 
them. In the last decade, several reports have shown the association of chronic C. pneumoniae 
infection with atherosclerosis and thrombosis and many studies have incriminated C. 
pneumoniae in the causation of coronary heart disease, stroke and asymptomatic carotid 
atherosclerosis. 
In fact, patients having an infection within a week before the onset of stroke might develop 
cortical middle cerebral artery infarcts, cardioembolic infarcts and arterial dissections 
suggesting a differential effect of infection. In older patients, various conventional risk 
factors (diabetes, hypertension, hypercholesterolemia, etc) play an important role in stroke 
etiopathogenesis. However, younger patients (aged <45years) usually lack these risk factors, 
and infections, especially in developing countries, may assume significance [8, 9]. It is 
therefore relevant to look for the role of infection in contributing to various subgroups of 
ischemic stroke in young patients [8].  
Bandaru et al found an association between the presence of C. pneumoniae antibodies and 
ischemic stroke among young Indian patients. They found that positive serum IgG and IgA 
antibody titer by microimmunofluorescence (MIF) test, against C. pneumoniae was 
significantly more in ischemic stroke patients compared to age and sex matched control 
subjects [8,9]. This is in agreement with previous studies where C. pneumoniae antibody 
positivity has been noted in young stroke patients [3, 47].  
In Cameroon, Njamnshi AK et al demonstrated that C. pneumoniae infection is significantly 
associated with ischemic stroke in patients in the < 50 years age group compared to matched 
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controls [47]. Another study also demonstrated that C. pneumoniae seropositivity can 
increase the risk of stroke in young patients aged below 55 years in which, C. pneumoniae 
seropositivity in all ischemic stroke subgroups except stroke of indeterminate etiology is 
found [8].  
C. pneumoniae infection causes atherosclerosis of large arteries by infecting the vascular 
endothelial cells, activation of the NF-ĸǃ, up regulation of procoagulant activity (tissue 
factor, plasminogen activator inhibitor), increased platelet count, adhesion molecules and 
finally thrombosis formation. The positivity of C. pneumoniae antibodies in 
nonatherosclerotic strokes like small artery disease and stroke of other determined etiology 
caused by pathophylogical changes due to lipohyalinosis or hypercoagulability may be an 
epiphenomenon. 
CRP is a marker of inflammation. Several studies have found that C. pneumoniae infection 
could contribute to elevation of CRP levels and to the instability or progression of 
atherosclerotic plaques. In the study of Bandaru et al, both C. pneumoniae and CRP positivity 
was found in 29% of patients and it was significantly associated with stroke compared to 
controls subjects [8]. Hasan found that Chronic C. pneumoniae infection demonstrated by 
positive IgA-type antibody can be considered a significant risk for ischemic stroke [31]. 
If persistent C. pneumoniae infection contributes to vascular events such as stroke, it is 
interesting from a therapeutic perspective.  Although C .pneumoniae may contribute to the 
risk of stroke directly, in most cases, it acts in concordance with the conventional risk 
factors. In younger individuals with ischemic stroke in whom C. pneumoniae found to be a 
risk factor, eradication of infection by antibiotic treatment may decrease the risk of stroke 
[3,8,9, 47]. 
3.3 Alzheimer's disease  
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Symptoms 
include progressive memory loss, decreased cognition, problems with spacial and 
perceptual recognition, and impairment of daily living. The hallmark of Alzheimer's disease 
is the extracellular accumulation and deposition of insoluble amyloid, to be found in the 
parenchyma in the form of amyloid plaques and in meningeal and cerebral vessels as a 
congophile angiopathy. Amyloid plaques and neurofibrillary tangles are characteristic, but 
not specific to Alzheimer's disease. Similar changes can be found in healthy ageing 
processes and in various other neurodegenerative diseases.  It is common to differentiate 
between an early-onset, familial Alzheimer's disease( FAD) with an established genetic 
etiology, representing only about 5% of all cases, and the more typical late-onset, sporadic 
Alzheimer's disease (LOAD)with an age of onset above 65 years and no clear pattern of 
inheritance [39]. The development of LOAD, the most prevalent form of AD, is believed to 
be a multifactorial process that may also involve infections with bacterial or viral pathogens. 
After the first report on the presence of C. pneumoniae in brains of patients with AD 
appeared in 1998, this bacterium has most often been implicated in AD pathogenesis. 
However, while some studies demonstrate a clear association between C. pneumoniae 
infection and AD, others have failed to confirm these findings [38]. 
Sporadic, late-onset Alzheimer's disease (LOAD) is actually a non-familial, progressive 
neurodegenerative disease that is now the most common and severe form of dementia in the 
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elderly. That dementia is a direct result of neuronal damage and loss associated with 
accumulations of abnormal protein deposits in the brain. Great strides have been made in 
the past 20 years with regard to understanding the pathological entities that arise in the AD 
brain, both for familial AD (approximately 5% of all cases) and LOAD (approximately 95% 
of all cases [39]. 
Some indirect evidence seems to suggest that infection with C. pneumoniae might be 
associated with the disease. Nucleic acids prepared from those samples were screened by 
polymerase chain reaction (PCR) assay for DNA sequences from the bacterium and showed 
that brain areas with typical AD-related neuropathology were positive for the organism in 
17/19 AD patients [7, 26, 39]. Electron- and immunoelectron-microscopic studies of tissues 
from affected AD brain regions identified chlamydial elementary and reticulate bodies, but 
similar examinations of non-AD brains were negative for the bacterium. Culture studies of a 
subset of affected AD brain tissues for C. pneumoniae were strongly positive, while 
identically performed analyses of non-AD brain tissues were negative [39]. Reverse 
transcription (RT)-PCR assays using RNA from affected areas of AD brains confirmed that 
transcripts from two important C. pneumoniae genes were present in those samples but not 
in controls. Immunohistochemical examination of AD brains, but not those of controls, 
identified C. pneumoniae within pericytes, microglia, and astroglia [7, 26]. Further 
immunolabelling studies confirmed the organisms' intracellular presence primarily in areas 
of neuropathology in the AD brain. Thus, C. pneumoniae is present, viable, and 
transcriptionally active in areas of neuropathology in the AD brain, possibly suggesting that 
infection with the organism is a risk factor for late-onset AD [41]. In other study, 
Immunohistochemical analyses showed that astrocytes, microglia, and neurons all served as 
host cells for C. pneumoniae in the AD brain, and that infected cells were found in close 
proximity to both neuritic senile plaques and neurofibrillary tangles in the AD brain [26, 41].    
The importance of inflammation in the pathogenesis of neurodegenerative disorders, such 
as Alzheimer's disease, is increasingly being recognized. Although amyloid-beta is 
considered to be one of the main initiators of these inflammatory processes, some reports 
suggest that brain infections may also contribute or even initiate the neuroinflammation 
[39]. Recent data showed the role of C. pneumoniae infection in neuroinflammation and its 
potential contribution to the pathogenesis of Alzheimer's disease [7]. 
In an experimental trend, amyloid deposits resembling plaques found in Alzheimer's 
disease (AD) brains were formed in the brains of non-transgenic BALB/c mice following 
intranasal infection with C. pneumoniae. The mice were infected at 3 months of age with C. 
pneumoniae isolated from an AD brain. Infection was confirmed by light and electron 
microscopy in olfactory tissues of the mice. C. pneumoniae was still evident in these tissues 
3 months after the initial infection indicating that a persistent infection had been 
established [41]. 
Medications (for example, antibiotics and anti-inflammatory drugs) prescribed to older 
individuals could affect the phenotypic and persistent nature of the organism, especially in 
the brains of patients with AD [11]. The proinflammatory response following infection may 
result in damage to C. pneumoniae as a result of evoked bacteriostatic events such as free 
radical damage in the tissues and/or nutrient starvation of the organisms [39]. In this 
regard, typical and atypical forms of C. pneumoniae were observed in the AD-affected brain. 
The main phenotypical differences were exhibited in the overall shape and size of the 
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organisms, but immunoreactivity to the organism in the brain was similar to that of C. 
pneumoniae laboratory strains [4]. 
Inflammation is common in the AD brain in areas of neuropathology. This inflammation has 
been advanced as a pathogenic mechanism in the disease. Indeed, inflammation has been 
implicated as an important factor in a number of diseases, and one study indicated that 
administration of nonsteroidal antiinflammatory drugs could be beneficial in treating AD 
[11]. Because chlamydial infection engenders a strong inflammatory response, infection by 
C. pneumoniae, in part, may be responsible for the inflammation observed in the AD affected 
brain [39]. The results of Balin study demonstrated the frequent infection of microglia and 
astroglia with C. pneumoniae in the AD-affected brain [7]. Intriguingly, an animal model, in 
which low-dose infusion of LPS has been used, revealed remarkable parallels with AD 
inflammation including APP induction, increased cytokine production with microglial 
reactivity, and temporal lobe pathology [41]. 
Microglia are the resident tissue macrophages of the brain, and once activated they, like 
astroglia, are a source of inflammatory cytokines, including IL-1, TNF, and IL-6. Another 
study also showed that the infected cells in the AD-affected brains were microglia, astroglia, 
perivascular pericytes, and macrophages. These findings and an in vitro studies suggest that 
the glial cells and blood monocytes that traffic into the brain are primarily infected with C 
pneumoniae [39]. 
The fundamental question that must be answered is whether this organism could be a 
causative agent or an opportunist that finds its way into damaged tissues. In either case, the 
organism’s presence in AD can affect aspects of symptomatology and progession that have 
their roots in the inflammation and blood vessel damage currently thought to play 
significant roles in this disease. 
3.4 Vasculitis induced by Chlamydia pneumoniae 
3.4.1 Giant cell arteritis, polymyalgia rheumatica, temporal arteritis  
The possibility of infectious triggers stimulating the development of inflammatory vascular 
diseases has generated much recent interest. Giant cell arteritis (GCA) is a vasculitis disease 
affecting medium- to large-sized arteries. The disease is an inflammation of these arteries, 
mainly of the outermost of their three layers. It is known to be associated with previous 
upper respiratory tract symptoms. The occurrence of cases is often clustered in certain time 
periods and geographic locations. It is primarily a disease of the elderly, and is more 
common in women than in men. Fever of unknown origin is one of the symptoms along 
with polymyalgia rheumatica (PMR), a related clinical syndrome, that is strongly associated 
with DR4 positivity [43, 44]. 
Several recent studies in which activated CD41 T cells were identified in arteries of patients 
with GCA have strongly suggested that this disease might be antigen driven although the 
relevant antigens have not been identified as yet. In the search for the disease-inducing 
antigens in GCA, a number of different parameters have been suggested to be important. 
For example, the clustering of cases in specific time periods and in particular geographic 
locations indicates that in addition to genetic predispositions for the disease, environmental 
or seasonal factors may be significant. Moreover, GCA and polymyalgia rheumatica (PMR) 
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are related clinical syndromes that affect the elderly. This association is supported by the 
close similarity in the clinical patterns of both, and the striking association of both with DR4 
positivity [43, 44, 45]. 
Importantly, upper respiratory tract symptoms are often recognized as part of the syndrome 
in both GCA and PMR. In this respect, some reports have suggested that Chlamydia 
pneumoniae might be involved in the pathogenesis of vasculitis. In clinical practice, it is a 
common observation that the onset of so-called noninfectious vasculitis is often preceded by 
symptoms of upper respiratory tract infection, although a specific infecting agent is only 
occasionally recovered in laboratory analysis of such patients. In addition, a number of 
recent studies have indicated renewed interest in assessing the association between 
atherosclerosis and vasculitis [44, 45]. 
Several publications have addressed the interaction among infection, inflammation, and 
traditional risk factors in atherosclerosis and coronary artery disease [43]. Some clinical and 
laboratory studies have demonstrated the presence of C. pneumoniae in atherosclerotic 
tissues from diverse anatomic locations, suggesting that this bacterium may be involved in 
the pathogenesis of that disease [10, 58].  
Two studies have presented evidence of a coincidence of cyclic fluctuations of Chlamydia 
pneumoniae epidemics and cases of GCA [52, 53]. Really conflicting data exist regarding the 
role of C. pneumoniae in the pathogenesis of GCA. Some authors found a strong correlation 
between GCA and detection of C. pneumoniae [51]. In another study, 8 of 9 GCA patients 
were PCR-positive for C. pneumoniae, while the only one of nine controls who was positive for 
C.pneumonia had respiratory symptoms [51]. In some of the tissue specimens, C. pneumoniae 
was found outside of cells, "possibly suggesting that the organism was viable and undergoing 
active vegetative growth in temporal artery tissues in GCA patients" [52, 53].  
Positive correlation between the presence of Chlamydia pneumoniae in temporal artery biopsy 
specimens and the diagnosis of temporal arteritis (TA) is found in the study of Regan et al 
using sensitive and specific PCR. Analyses showed that all 90 patients were confirmed to 
have met the American College of Rheumatology classification criteria for TA [51].  The 
results of this study and study of Cooper et al [15] do not support a role for C. pneumoniae in 
the pathogenesis of TA. 
Kaperonis et al investigated the association of inflammation and Chlamydia pneumoniae 
infection with the presence and severity of peripheral arterial disease. This study supports 
the hypothesis that inflammation (CRP) and chronic C. pneumoniae infection (IgA 
seropositivity), have an important role in lower limb atherosclerosis and correlate with the 
severity of the disease [37]. 
3.4.2 Vascular dementia 
Vascular dementia is characterized by a loss of cognitive function and social adaptive 
functions in individuals with cerebrovascular disease. Vascular dementia is the second most 
common cause of dementia (second only to Alzheimer's disease) and accounts for 10% to 
15% of all cases. The clinical presentation of this illness is variable, depending on the site 
and extent of the lesion or infarct. The pathogenesis of vascular dementia has not been well 
defined. Chronic inflammation and cytokine dysregulation may play a role similar to that 
seen in Alzheimer's disease.  
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Recent data from serological and PCR studies support an association between C. 
pneumoniae and some cerebrovascular disease. C.pneumonia has been associated with 
stroke, transient cerebral ischemia, and atherosclerosis in the middle cerebral artery in both 
prospective and case-control studies [13, 64]. Since stroke is an important precursor to 
vascular dementia, these data raise the possibility that C.pneumonia infection may also be a 
risk factor for vascular dementia. 
C.pneumonia serology is an imperfect test of C. pneumoniae exposure and chronic infection. 
First, the high prevalence of C.pneumonia exposure makes it difficult to detect true 
serological differences between cases and controls. Second, it is unclear what the 
appropriate serological cut-offs should be for identifying exposure versus chronic infection 
or recent infections [18]. As a result, different groups have used different criteria making 
comparisons across studies more difficult. However, the importance of this inconsistency is 
unclear. 
There is an extensive literature supporting an association between C.pneumonia and 
atherosclerosis. Although the majority of these studies initially focused on coronary heart 
disease [10, 15, 16]. More recent evidence also supports an association with stroke [14]. 
However, the clinical importance of this association is uncertain. Carusone et al, found no 
significant association between elevated or high C. pneumoniae specific IgG or IgA 
antibodies and vascular dementia [13].  In this study, the odds ratio estimate for IgA titres 
was slightly higher than IgG titres, but not statistically different. The meaning of this 
difference is uncertain. Danesh et al suggest that these differences are likely due to chance, 
selection biases, or selective emphasis on particular reports [16]. The odds ratio estimate 
for IgA titres is also slightly higher than IgG titres, but not statistically different.  
Carusone et al suggest that the odds ratio estimates for elevated IgA and IgG antibodies 
do not definitively rule out an association between antibodies and vascular dementia 
because the relatively small sample[13]. Other studies have suggested that IgA titres are 
more strongly associated with disease outcomes because they are a better indicator of 
chronic C.pneumonia infection [14].  
It is now widely believed that vascular risk factors are also associated with Alzheimer's 
disease and Alzheimer's and vascular dementia may share many common clinical and 
pathological characteristics [39]. A number of studies have examined the association 
between Alzheimer's disease and C.pneumonia infection. Balin et al found an extremely high 
association between the presence of C.pneumonia in post-mortem brain samples and late-
onset Alzheimer's disease [7]. However, more recent studies have not repeated these 
findings one study has looked for C.pneumonia in brain samples of vascular dementia 
patients. This study, like the later AD studies, did not identify C.pneumonia in any of the 
brain samples [72]. These results suggest that the presence of C.pneumonia in the brains is 
not strongly associated with late-onset Alzheimer's disease or vascular dementia. 
Inflammatory responses are also known to be associated with cardiovascular disease and 
have recently been implicated in dementia. Elevated levels of serum C-reactive protein 
(CRP), a non-specific marker of inflammation, predict cardiovascular disease and dementia, 
and have been associated with stroke patients [73]. Although CRP was originally thought to 
be produced almost exclusively by hepatocytes, CRP is now known to be synthesized in 
brain cells and upregulated in Alzheimer tissue [73]. 
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3.5 Atherosclerosis and coronary artery disease  
An association between coronary artery disease and other Atherosclerotic syndromes and C. 
pneumoniae infection has been suggested by both seroepidemiologic studies and the 
demonstration of the presence of the organism in athromatous plaque. The initial study 
indicating a possible association between C. pneumoniae and coronary artery disease was 
performed in Finland and showed that patients with coronary artery disease were 
significantly more likely to have serologic evidence of past infection with TWAR than were 
controls [55]. 
Morphologic and microbiologic evidence of the presence of C. pneumoniae in athermanous 
plaques has been obtained by electron microscopic studies of coronary atheroma, 
immunocytochemical staining and PCR testing of coronary, carotid, and aortic atheroma 
[60]. The organism has also been demonstrated in atheromatous tissue removed from 
patients by directional coronary atherectomy and was found more commonly in restenotic 
lesions than in primary lesions [12, 68]. Autopsy specimens from young persons (15 to 35 
years of age) has offered the opportunity to study coronary arteries from persons without 
atherosclerosis, an opportunity for control material not available in older adults [12, 68]. The 
organism was not detected by PCR or immunocytochemical staining in 31 coronary artery 
specimens that showed no atheroma but was demonstrated in 2 of 11 specimens showing 
probable early lesions (intimal thickening) and in 6 of 7 specimens with developed 
atherosclerotic plaques [33]. More recently, C. pneumonia seropositivity was associated with 
enhanced intima-media thickness of arteries. While these studies clearly associate TWAR 
organisms with atheromatous plaques, the role of TWAR infection in the pathogenesis of 
atherosclerosis is unknown [10, 36].  
Three types of evidence support the association of C. pneumoniae with atherosclerosis 
including seroepidemiological studies, direct detection of bacterial DNA or antigen, or both, 
in atherosclerotic lesions and isolation of the organism from athermanous tissue. Following 
the initial report of Saikku et al demonstrating an association of C. pneumoniae antibody with 
myocardial infarction and coronary heart disease [55], there have been more than 50 studies 
demonstrating a sero-epidemiological association between C. pneumoniae and cardiovascular 
disease. The strongest evidence for an association of C. pneumoniae with atherosclerosis has 
been the demonstration of C. pneumoniae by PCR, immunocytochemical staining and 
electron microscopy in atherosclerotic lesions and culture of the organism from atheromata 
[40, 70]. Within the atherosclerotic lesion, the organism has been detected in foam cells 
derived from macrophages and smooth muscle cells, a hallmark of early lesion formation, 
and also in endothelial cells. Although the percentage of atherosclerotic lesions in which the 
organism has been found covers a wide range and correlation between different detection 
methods has not been good, more than 45 peer-reviewed publications have confirmed the 
initial report of Shor et al demonstrating the organism in human of 272 atherosclerotic 
tissues tested and was not found in any of the 52 normal arteries tested [60]. Moreover, C. 
pneumoniae has not been detected in other granulomas, with the exception of sarcoid tissue, 
and has been found more frequently in atherosclerotic lesions than in other tissues from the 
same person, suggesting that the organism has a tropism for atheromas. These cumulative 
observational studies leave no question that C. pneumoniae is present in atherosclerotic 
lesions. Defining the pathogenic mechanisms by which C. pneumoniae infection could 
contribute to atherogenesis must be more investigated. 
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C. pneumoniae may infect circulatory components, which may attach to the endothelium 
and smooth muscle cells and kill them by apoptosis. The probable molecular mechanism of 
atherosclerosis pathogenesis can be explained by up-regulation of expression of heat shock 
protein 60 (HSP-60) by C. pneumoniae infection, which induces production of cytokines 
such as TNF-ǂ, IL-1ǃ and IL-6, and MMPs by macrophages. Furthermore, C. pneumoniae 
could lead to elevation of CRP and contribute to instability or progression of atherosclerotic 
plaques. The bacterium replicates in endothelial and smooth muscle cells and macrophages, 
and it can activate CD4+ and CD8+ T lymphocytes. C.pneumonia initiates inflammatory 
activation via the NF-κB pathway, resulting in increased expression of vascular cell 
adhesion molecule-1, enhanced recruitment of inflammatory leukocytes to the vessel wall, 
impaired activity of endothelial nitric oxide, increased platelet adhesion to endothelial cells 
and procoagulant activity in endothelial cells, as well as causing oxidation of LDL-C. 
Therefore, chronic infection may contribute to the risk of CHD by initiating a high level of 
immunologic activity, by raising triglyceride levels and decreasing HDL levels, and by 
increasing the concentrations of acute-phase reactants such as fibrinogen, CRP, and sialic 
acid [32   , 33]. 
3.6 Heart diseases, inflammatory diseases 
In vivo sites of chlamydial infection demonstrate chronic inflammation characterized by 
activated monocytes and macrophages. Immunopathogenesis resulting from inflammation 
is the hallmark for chlamydia-induced disease. Chlamydial infection may elicit the 
inflammatory response via up-regulated cytokine production in infected or neighboring 
cells. Ingredients for this elicitation can include direct infection, lipopolysaccharide 
stimulation (LPS found on the outer surface of C. pneumoniae), and/or production of heat 
shock proteins, such as Hsp60. Proinflammatory cytokines (IL-1, TNF, IL-6) and TH1-
associated cytokines such as IFN and IL-12 have been identified at sites of chlamydial 
infection[49, 50, 68].  
Chlamydia infections are epidemiologically linked to human heart disease. A peptide from 
the murine heart muscle-specific alpha myosin heavy chain that has sequence homology to 
the 60-kilodalton cysteine-rich outer membrane proteins of C. pneumoniae, C. psittaci, and C. 
trachomatis was shown to induce autoimmune inflammatory heart disease in mice [6, 54]. 
Injection of the homologous Chlamydia peptides into mice also induced perivascular 
inflammation, fibrotic changes, and blood vessel occlusion in the heart, as well as triggering 
T and B cell reactivity to the homologous endogenous heart muscle-specific peptide [6, 54]. 
Chlamydia DNA functioned as an adjuvant in the triggering of peptide-induced 
inflammatory heart disease. Infection with C. trachomatis led to the production of 
autoantibodies to heart muscle-specific epitopes [6, 54]. Thus, Chlamydia-mediated heart 
disease is induced by antigenic mimicry of a heart muscle-specific protein [12]. 
Heart disease is the most prevalent cause of morbidity and mortality in rich countries. 
Numerous clinical and experimental studies suggest that chronic stages of heart diseases 
are, at least in part, mediated by autoimmune responses to cardiac antigens [54]. 
Inflammatory heart disease is caused by a wide variety of pathogens such as viruses, 
bacteria, and protozoa [54,68]. RNA of the picornavirus Coxsackie B3 (CVB3) is detected in 
the heart muscle of 40%–50% of patients with dilated cardiomyopathy (DCM), which is 
defined by enlargement of cardiac chambers, thinning of ventricular walls, and reduced 
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myofibrillar contractility [71]. Several bacterial infections (e.g., with Chlamydia species in 
particular) are also epidemiologically linked to human heart disease [6, 12, 24].  
Because both Coxsackie virus and chlamydial infections are so common in humans, the 
identification of subsets of patients at risk of progression from acute infections to chronic 
cardiomyopathy is a large mystery. For example, who would do heart muscle biopsies in a 
patient with a common cold? Therefore, the challenge will be to identify both genetic and 
environmental factors that determine the progression to chronic heart disease and the 
development of DCM. Since autoinflammatory heart disease in humans can be reproduced 
in mice by immunization with heart muscle myosin, this experimental system has been used 
to analyze the immune response and host susceptibility.  
Infections with bacteria that carry peptides that mimic endogenous heart-specific and heart-
pathogenic epitopes lead to activation of autoaggressive lymphocytes. Pathogen-derived 
DNA contributes to immunactivation. The systemic effects of cytokines allow presentation 
of short cardiac myosin heavy chain (ǂ-isoform) peptides in association with MHC class II 
molecules and the up-regulation of adhesion and homing receptors on APC resident within 
the target organ. The TNF-Rp55 appears to be a crucial receptor that controls target organ 
susceptibility in autoimmune heart disease via up-regulation of MHC class II on heart 
interstitial cells. After initiation of the inflammatory process by CD4+ T cells, CD8+ cells and 
macrophages are recruited into the heart muscle and contribute to disease pathogenesis. In 
addition, activation of B cells and production of auto antibodies may be involved in the 
progression of heart disease. This molecular scenario of autoimmunity also suggests that 
induction of disease depends on a fine balance between activation of self-reactive T cells and 
target organ susceptibility. The challenge for the development of successful prevention and 
treatment strategies will be to diagnose those few at risk of developing severe heart disease 
among the many with chlamydial or Coxsackie virus infections [6,12,54] . 
3.7 Juvenile idiopathic arthritis 
Infectious agents have been implicated in the pathogenesis of many rheumatologic diseases. 
In most of these diseases, including those in which specific organisms are known to play a 
role, the details of pathogenesis remain incompletely defined. Recent studies have aimed to 
isolate bacterial and viral pathogens from patients with rheumatic diseases, efforts have 
been made to further define the host immune response to infection, and there have been 
attempts to develop improved methods of diagnosis and treatment of infectious diseases 
affecting the musculoskeletal system. 
Juvenile idiopathic arthritis (JIA) is a disease that was prominent with increased 
inflammation response in immune system, appeared mostly with peripheral arthritis. 
Endogenous and exogenous antigens play a role in the pathogenesis of disease. Two major 
reasons were thinking to be considerably important. First of them is immunological 
predisposition and the second one is environmental factors. Infections are considered to be 
the most important between environmental factors but also stress and trauma are also 
important in the etiology of the disease. However, the relation between JIA and infections is 
not clearly defined but the relation between adult chronic arthritis and infections was well-
defined [1, 2]. 
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Some investigators have suggested that C.pneumonia infection may be associated with 
atherosclerotic cardiovascular disease, asthma, multiple sclerosis and rheumatoid arthritis 
that is characterized by chronic inflammation of the synovium. Although C.pneumonia has 
been known to trigger a strong inflammatory response, there is no evidence to indicate a 
relationship between inflammation of the synovium and C.pneumonia [1, 5]. It is also not 
clear whether this micro-organism can trigger or exacerbate erosive joint damage. Taylor-
Robinson et al investigated the relationship between JIA and C.pneumonia and suggested that 
larger studies with control groups were needed for more conclusive results [64].  
The relationships between chronic synovitis and different bacteria, including mycobacteria, 
and viruses have been extensively studied by several investigators [1, 35].  Recently, 
detection methods for genetic material originating from micro-organisms in joint fluids have 
become readily available. Thus, a hypothesis stating that chronic synovitis is an 
immunological response to bacterial toxins has become more popular [30, 63].  
Villareal focused on the role of C.pneumonia, which has a high prevalence amongst the 
general population, in the pathogenesis of chronic arthritis [65]. It was shown that 
C.pneumonia and C. trachomatis can spread to other anatomical locations by dissemination 
and cause chronic infections. Hannu  evaluated 35 adults with reactive arthritis and 
demonstrated positive serology for C.pneumonia infection in four patients. These 
investigators also demonstrated that three patients had recently recovered from a lower 
respiratory tract disease [30]. With these findings, the authors reported that the reactive 
arthritis of these patients had been triggered by C.pneumonia, which could therefore be one 
of the triggering agents in the etiology of reactive arthritis [30, 64].  
Taylor-Robinson et al investigated the relationship between JIA and C. pneumoniae in 19 
children with JIA and showed that, C.pneumonia IgG antibodies were determinable in ten 
patients, but C.pneumonia DNA was found in only one child [64]. The presence of very high 
antibody titres in synovial fluids from this patient, along with another child with negative 
results for C.pneumonia DNA, suggested that the antibody may have been produced in the 
synovium [64]. 
It has been reported that C. pneumoniae can evoke a local inflammatory response when it is 
carried to the joint fluid.  Gerard and Schumacher  evaluated 212 patients with arthritis and 
reported C. pneumoniae DNA was present in synovial tissues of 13 % patients, but it was 
found in synovial fluids of only 4 % controls [25].  
Wilkinson found C. trachomatis DNA in rheumatoid arthritis patients and in nearly one-third 
of unselected patients with undifferentiated oligoarthritis, which further supports the 
hypothesis that it plays an important role in disease pathogenesis. However, its presence 
did not correlate with evidence of an antichlamydial immune response. Despite previous 
anecdotal reports, C. pneumoniae does not appear to be a major cause of undifferentiated 
oligoarthritis or rheumatoid arthritis [69]. 
3.8 Diabetes 
Obesity-associated chronic diseases, such as type 2 diabetes and atherosclerosis, are driven 
by inflammatory mediators, such as tumour necrosis factor-a (TNF-ǂ) [71], which are also 
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expressed during infection. Epidemiological and pathological evidence has long linked 
highly prevalent chronic pathogens (i.e., Chlamydia pneumoniae, Helicobacter pylori, 
Porphyromonas gingivalis, hepatitis C virus, human immunodeficiency virus, influenza 
virus, cytomegalovirus, and herpes simplex virus type 1) to metabolic syndrome, insulin 
resistance type 2 diabetes, and coronary artery disease. C.pneumonia infection occurs with 
high frequency in virtually all humans during their lifetime, and numerous studies have 
demonstrated strong links between C.pneumonia infection and metabolic syndrome, 
insulin resistance, and coronary artery disease [46]. However, the cause and relationship 
has remained inconclusive, and the link was not confirmed in some studies or 
disappeared after controlling for body weight [17, 22]. Moreover, preventive antibiotic 
treatment failed to reduce the prevalence of secondary coronary events in large clinical 
trials, including a 4012-patient trial that tested a 1-year course of weekly azithromycin 
administration [29, 44- 46]. 
Murine C.pneumonia infection enhanced insulin resistance development in a genetically and 
nutritionally restricted manner via circulating mediators. The relevance for the current 
human diabetes epidemic remains to be determined, but this finding is potentially 
important because of the high prevalence of human C.pneumonia infection worldwide. 
Fernández et al investigated the relationship between C. pneumoniae infection and 
peripheral arterial occlusive disease (PAOD) by analyzing clinical samples from 95 
patients with PAD and 100 controls [22]. They did not find significant differences in anti-
LPS IgG, anti-LPS IgA and anti-EB IgA between cases and controls but C. pneumoniae 
DNA findings in the vascular wall biopsy showed significant differences between cases 
and controls. This study showed significantly relationship between C. pneumoniae 
infection with PAD through the detection of anti-EB IgG from serum and bacterial DNA 
from arterial biopsy [22].  Study of Gutiérrez et al also showed that PAOD is significantly 
associated with C. pneumoniae infection through the detection of anti-EB IgG from serum 
and bacterial DNA from arterial biopsy [29]. 
3.9 Uveitis 
The most common form of uveitis is anterior uveitis, which involves inflammation in the 
front part of the eye. It is often called iritis because it is usually only effects the iris, the 
colored part of the eye. The inflammation may be associated with autoimmune diseases, but 
most cases occur in healthy people. The disorder may affect only one eye. It is most common 
in young and middle-aged people. Posterior uveitis affects the back part of the uvea, and 
involves primarily the choroid, a layer of blood vessels and connective tissue in the middle 
part of the eye. This type of uveitis is called choroiditis. If the retina is also involved it is 
called chorioretinitis. Anterior uveitis is the most common form, and occurs annually at a 
frequency of about 8 to 15 cases per 100,000 people. This type of uveitis affects men and 
women equally. [34, 48]. 
Numazaki K et al found that the prevalence of serum IgA and IgM antibodies to C. 
pneumoniae in patients with endogenous uveitis associated with sarcoidosis was significantly 
higher than that in patients with other endogenous uveitis [48]. Huhtinen et al investigated 
the prevalence of antibodies to C. pneumoniae Hsp60 in patients with acute anterior uveitis 
www.intechopen.com
 
Pathogenesis of Chlamydia pneumonia Persistent Illnesses in Autoimmune Diseases 299 
[34]. They did not find significantly difference in frequency and the level of IgG antibodies 
to C. pneumoniae Hsp60 between the patients and control subjects but the levels of IgA 
antibodies to C. pneumoniae Hsp60 were significantly higher in the patients than in the 
control subjects [48]. 
4. Conclusion 
Immunological studies performed in animal models of autoimmune diseases strongly 
suggest that infections represent the best candidates for the environmental factors triggering 
human autoimmune disease. Only limited data are available as yet which show strong 
indications in this direction. However, the bulk of indirect evidence is serological data and 
important role of interferon-a in a number of autoimmune diseases, argue in favor of an 
etiological role for infections. More recently, C.pneumonia has been linked to a number of 
chronic human diseases and many autoimmune diseases with involving chronic 
inflammation and demyelination. The possible mechanisms of C.pneumonia involvement as 
aetiological agents or in the exacerbation of these diseases have been investigated 
intensively. Two basic elements are the association between bacterial infection and 
autoimmune disease and the involvement of the immune system in the disease process. We 
hope that the numerous studies in progress will provide the possibility of identifying the 
role of C.pneumonia in related autoimmune diseases. This would be important for the 
understanding of disease pathogenesis. It might prove of crucial clinical interest by opening 
up major therapeutic perspectives including anti-infectious agents, chemicals and 
monoclonal antibodies and vaccination. 
5. References 
[1] Albert LJ (2000). Infection and rheumatoid arthritis: guilt by association? J Rheumatol 
,Vol.37, pp. 564–566. 
[2] Altun, S.,  Kasapcopur, O.,  Aslan ,M., et al (2004). Is there any relationship between 
Chlamydophila pneumoniae infection and juvenile idiopathic arthritis? J Med 
Microbiol ,Vol.53, No.8, pp. 787-790 
[3] Anzini, A., Cassone, A., Rasura, M., et al (2004). Chlamydia pneumoniae infection in young 
stroke patients: a case control study. Eur J Neurol  , Vol.11, No.5, pp. 321-7. 
[4] Arking, EJ.,Appelt, DM., Abrams, JT., Kolbe, S., Hudson, AP., & Balin, BJ (1999). 
Ultrastructural analysis of C .pneumoniae in the Alzheimer’s brain. Pathogen , Vol.1, 
pp. 201-211. 
[5] Aslan, M., Kasapcopur, O., Yasar, H., et al (2011).  Do infections trigger juvenile 
idiopathic arthritis? Rheumatol Int , Vol.31, No.2, pp. 215-20.  
[6] Bachmaier K., Neu N., de la Maza LM., Pal S., Hessel A., & Penninger, JM (1999). 
Chlamydia infections and heart disease linked through antigenic mimicry. Science , 
Vol.283, No.5406, pp. 1335-9. 
[7] Balin, BJ., Little, CS., Hammond, CJ., Appelt, DM., Whittum-Hudson, JA., Gérard HC., & 
Hudson AP (2008). Chlamydophila pneumoniae and the etiology of late-onset 
Alzheimer's disease. J Alzheimers Dis , Vol.13, No.4, pp. 371-80. 
www.intechopen.com
 
Chlamydia 300 
[8] Bandaru, VC., Laxmi, V., Neeraja, M., et al (2008). Chlamydia pneumoniae antibodies in 
various subtypes of ischemic stroke in Indian patients. J Neurol Sci , Vol.15, No.272, 
pp. 115-22 
[9] Bandaru, VC.,  Babu Boddu,  D.,  Laxmi, V.,  Neeraja M.,  & Kaul, S (2009). 
Seroprevalence of Chlamydia Pneumoniae Antibodies in Stroke in Young. Can J  
Neurological Sci , Vol.36, No.6, pp. 725-29 
[10] Belland, RJ., Ouellette, SP., Gieffers, J., & Byrne, GI (2004). Chlamydia pneumoniae and 
atherosclerosis. Cell Microbiol , Vol.6, pp. 117–127.   
[11] Breitner, JC (1996). The role of anti-inflammatory drugs in the prevention and treatment 
of Alzheimer’s disease. Ann Rev Med  ,  vol.47,  pp.401-411. 
[12] Campbell, LA., Kuo, C-C., Grayston, JT (1998). Chlamydia pneumoniae and 
cardiovascular disease. Emerg Infect Dis , Vol. 4 , pp.571–579 
[13] Carusone, SC., Smieja, M., Molloy, W., et al (2004) .Lack of association between vascular 
dementia and Chlamydia pneumoniae infection: a case-control study. BMC Neurol , 
Vol. 4 , pp. 15.  
[14] Cook, PJ., Honeybourne, D., Lip, GY., Beevers, DG., Wise, R., & Davies, P (1998). 
Chlamydia pneumoniae antibody titers are significantly associated with acute stroke 
and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke , Vol.29 
, pp.404–410. 
[15] Cooper, RJ ., D'Arcy, S.,Kirby, M., Al-Buhtori, M., Rahman , MJ., Proctor, L., & Bonshek, 
RE(2008). Infection and temporal arteritis: a PCR-based study to detect pathogens 
in temporal artery biopsy specimens. J Med Virol , Vol. 80, No.3, pp.501-5. 
[16] Danesh, J., Whnicup, P., Lewington, S., et al (2002). Chlamydia pneumoniae IgA titers and 
coronary heart disease. Eur Heart J  , Vol.23, No.5, pp.  371-5. 
[17] Dart, AM., Martin, JL., & Kay, S (2002). Association between past infection with 
Chlamydia pneumoniae and body mass index, low-density lipoprotein particle size 
and fasting insulin. Int J Obes Relat Metab Disord  , Vol.26 , pp.464-8. 
[18] Dowell, SF., Boman, J., Carlone, GM., et al (2001). Standardizing Chlamydia pneumoniae 
assays: recommendations from the Centers for Disease Control and Prevention 
(USA) and the Laboratory Center for Diseases (Canada). Clin infect Dis , Vol.33, 
No.4, pp. 492-503. 
[19] Engelhart, MJ., Geerlings, MI., Meijer, J., et al (2004). Inflammatory proteins in plasma 
and the risk of dementia: the Rotterdam Study. Arch Neurol ,   Vol.61, pp.668–672.   
[20] Ercolini, AM., & Miller, SD (2009). The role of infections in autoimmune disease. Clin 
Exp Immunol  , Vol.155, No.1, pp.1–15. 
[21] Fairweather, D., Kaya, Z., Shellam, GR., Lawson, CM., & Rose NR (2001). From 
infection to autoimmunity. J Autoimmun , Vol.16, pp. 175–86. 
[22] Fernández-Real, JM., López-Bermejo, A., Vendrell, J., Ferri, MJ., & Recasens, M (2006). 
Burden of infection and insulin resistance in healthy middle-aged men. Diabetes 
Care , Vol. 29 pp.1058-64. 
[23] Fujinami, RS., von Herrath, MG.,Christen, U., & Lindsay Whitton J(2006). Molecular 
Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune 
Disease. Clin Microbiol Rev , Vol.19, No.1, pp.80–94 
www.intechopen.com
 
Pathogenesis of Chlamydia pneumonia Persistent Illnesses in Autoimmune Diseases 301 
[24] Fujita, M., Hatachi, S., & Yagita, M (2009). Acute Chlamydia pneumoniae infection in the 
pathogenesis of autoimmune diseases. Lupus , Vol.18, No.2, pp. 164-168. 
[25] Gerard, HC., Schumacher, HR., El-Gabalawy, H., Goldbach-Mansky, R., & Hudson, AP 
(2000). Chlamydia pneumoniae present in the human synovium are viable and 
metabolically active. Microb Pathog , Vol.29 , pp.17–24. 
[26] Gérard, HC., Dreses-Werringloer, U., Wildt, KS., et al (2006). Chlamydophila (Chlamydia) 
pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol , Vol.48, No.3, 
pp.355-66. 
[27] Grayston JT (1992). Infections caused by Chlamydia pneumonia strain TWAR. Clin Infect 
Dis , Vol.15 , pp.757–763. 
[28] Grayston, JT., Kronmal, RA., Jackson, LA., et al (2005). Azithromycin for the secondary 
prevention of coronary events. N Engl J Med, Vol , 352 , pp.637-45. 
[29] Gutiérrez, J., Linares, J., Fernández, F., et al (2004). Relationship between the peripheral 
arterial occlusive disease and the infection by Chlamydophila pneumoniae. Med Clin 
(Barc), Vol.123, No.15, pp. 561-6. 
[30] Hannu, T, Puolakkainen,  M, Leirisalo-Repo,  M(1999). Chlamydia pneumoniae as a 
triggering infection in reactive arthritis. Rheumatology,  Vol.38, pp.411–414. 
[31] Hasan ZN (2011). Association of Chlamydia pneumoniae serology and ischemic stroke. 
South Med J  , Vol.104, No.5, pp. 319-21 
[32] Hong, MK. , Mintz, GS., Lee, CW., et al (2004). Comparison of coronary plaque rupture 
between stable angina and acute myocardial infarction: a three-vessel intravascular 
ultrasound study in 235 patients. Circulation , Vol.110, pp.928-933 
[33] Hortovanyi, E., Illyes, G., Kadar, A (2003). Early Atherosclerosis and Chlamydia 
Pneumoniae Infection in the Coronary Arteries. Pathology Oncology Research , Vol.19, 
No.1, pp. 42-46 
[34] Huhtinen, M., Puolakkainen, M., Laasila, K., Sarvas, M., Karma, A., & Leirisalo –Repo, 
M (2001). Chlamydial antibodies in patients with previous acute anterior uveitis. 
Invest Ophthalmol Vis Sci, Vol.42, No.8, pp.1816-1819. 
[35] Inman, RD., Whittum-Hudson, JA., Schumacher, HR., & Hudson, AP (2000). Chlamydia 
and associated arthritis. Curr Opin Rheumatol ,Vol.12, pp. 254-263. 
[36] Kalayoglu, MV, Libby, P, & Byrne, GI (2002). Chlamydia pneumoniae as an emerging risk 
factor in cardiovascular disease. JAMA , Vol.288, pp.2724–2731.   
[37] Kaperonis, EA., Liapis, CD., Kakisis, JD., et al (2006). Inflammation and Chlamydia 
pneumoniae infection correlate with the severity of peripheral arterial disease. Eur J 
Vasc Endovasc Surg , Vol.31, No.5, pp. 509-15. 
[38] Koskiniemi, M., Gencay, M., Salonen, O., et al (1996). Chlamydia pneumoniae associated 
with central nervous system infections. Eur J Neurol , Vol. 36, pp.160–163. 
[39] Kratzsch, T., Peters, J., & Frolich, L (2002). Etiology and pathogenesis of Alzheimer 
dementia. Wien Med Wochenschr , Vol.152, No.3-4, pp.72-6. 
[40] Kuo, CC , Chen, HH , Wang,  P , & Grayston, JT (1986). Identification of an new group 
of Chlamydia psittaci strains called TWAR. J Clin  Microbiol ,Vol. 24,pp.1034–1037. 
[41] Little, CS., Hammond, CJ., MacIntyre, A., Balin, BJ., & Appelt, DM (2004). Chlamydia 
pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. 
Neurobiol Aging , Vol.25, No.4, pp.419-29. 
www.intechopen.com
 
Chlamydia 302 
[42] Liu, R., Yamamoto, M., Moroi, M., et al (2005). Chlamydia pneumoniae immunoreactivity 
in coronary artery plaques of patients with acute coronary syndromes and its 
relation with serology. Am Heart J ,Vol.150 , pp. 681-688. 
[43] Ljungstrom, L, Franzen, C, Schlaug, M, Elowson, S, & Viidas, U(1997). Reinfection with 
Chlamydia pneumoniae may induce isolated and systemic vasculitis in small and 
large vessels. Scand J Infect Dis , Vol.104, Suppl pp.37–40. 
[44] Mehta, JL., Saldeen, TGP., & Rand, K (1998). Interactive role of infection, inflammation 
and traditional risk factors in artherosclerosis and coronary artery disease. J Am 
Coll Cardiol , Vol.31,pp.1217–25. 
[45] Muhlestein JB (2002). Secondary prevention of coronary artery disease with 
antimicrobials: current status and future directions. Am J Cardiovasc Drugs , Vol.2 , 
pp.107-18. 
[46] Nabipour, I., Vahdat, K., Jafari, SM., Pazoki, R., & Sanjdideh, Z (2006). The association 
of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, 
cytomegalovirus, and herpes simplex virus type 1: the Persian Gulf Healthy Heart 
Study. Cardiovasc Diabetol ,Vol.5 ,pp.25. 
[47] Njamnshi, AK., Blackett, KN., Mbagbaw, JN., Gumedze, F., Gupta, S., & Wiysonge, CS 
(2006). Chronic Chlamydia pneumoniae infection and stroke in Cameroon. Stroke, 
Vol.37, No.3, pp. 796-9. 
[48] Numazaki, K., Chiba, S., Aoki, K., Suzuki, K., & Ohno, S (1997). Detection of serum 
antibodies to Chlamydia pneumoniae in patients with endogenous uveitis and acute 
conjunctivitis. Clin Infect Dis , Vol.25, pp.928-929. 
[49] Peeling, RW., & Brunham, RC(1996). Chlamydiae as pathogens: new species and new 
issues. Emerg Infect Dis , Vol. 2 , pp. 307–319. 
[50] Posnett, DN., & Yarilin, D (2005). Amplification of autoimmune disease by infection. 
Arthritis Res Ther ,  Vol.7, No.2, pp.74–84. 
[51] Regan, MJ., Wood, BJ., Hsieh, YH., et al (2002). Temporal arteritis and Chlamydia 
pneumoniae: failure to detect the organism by polymerase chain reaction in ninety 
cases and ninety controls. Arthritis Rheum, Vol.46, No.4, pp.1056-60. 
[52] Rimenti, GF., Cosentini, BR., Moling,  O., Pristera,  R., Tarsia,  P., Vedovelli, C., & Mian, 
P (2000).Temporal arteritis associated with Chlamydia pneumoniae DNA detected in 
an artery specimen. J Rheumatol ,Vol.27 , pp.2718-2720. 
[53] Rimenti, EA., Liapis, CD., Kakisis, JD., et al (2006). Inflammation and Chlamydia 
pneumoniae infection correlate with the severity of peripheral arterial disease. Eur J 
Vasc Endovasc Surg , Vol.31, No.5, pp. 509-15. 
[54] Rose, NR (1996). Myocarditis: from infection to autoimmunity. The Immunologist   , Vol. 
4 , pp.67-75. 
[55] Saikku , P., Mattila, K., Nieminen, MS., Makela, PH.,Huttunen, JK., & Valtonen,  
V(1988). Serological evidence of an association of a novel chlamydia, TWAR, with 
chronic coronary heart disease and acute myocardial infarction. Lancet ii, pp.983–
986. 
[56] Schneider, R., & Passo, MH (2002). Juvenile rheumatoid arthritis. Rheum Dis Clin North 
Am, Vol. 28 , pp. 503–530. 
www.intechopen.com
 
Pathogenesis of Chlamydia pneumonia Persistent Illnesses in Autoimmune Diseases 303 
[57] Scolding, NJ., Zajicek, JP., Wood, N., & Compston, DAS (1994). The pathogenesis of 
demyelinating disease. Progr Neurobiol  ; 43: 143–173. 
[58] Sherbet, G (2009). Bacterial infections and the pathogenesis of autoimmune conditions. 
BJMP , Vol.2, No.1, pp.6-13. 
[59] Shoenfeld Y., et al (2008). The mosaic of autoimmunity: hormonal and environ mental 
factors involved in autoimmune diseases. Isr Med Assoc J  , Vol.10, pp. 8- 12 
[60] Shor, A., Kuo, CC., & Patton, DL (1992). Detection of Chlamydia pneumoniae in the 
coronary artery atheroma plaque. South Afr Med J ,Vol.82, pp.158–161 
[61] Sinha, AA., Lopez, MT., & McDevitt, HO (1990). Autoimmune diseases: the failure of 
self tolerance. Science , Vol.248 , pp.1380-88. 
[62] Sriram, S., Mitchell, W., & Stratton, C (1998). Multiple Sclerosis associated with 
Chlamydia Pneumoniae infection of the CNS. Neurology , Vol.50 ,pp. 571-572 
[63] Sriram, S., Steratton., CW, Yao., S, et al (1999). Chlamydia Pneumoniae infection of the 
Central Nervous System in Multiple Sclerosis. Ann Neurol , Vol.46 ,pp. 6-14 
[64] Taylor-Robinson, D., Thomas, B., & Rooney, M (1998). Association of Chlamydia 
pneumoniae with chronic juvenile arthritis. Eur J Clin Microbiol Infect Dis, Vol.17, pp. 
211-212. 
[65] Villareal, C., Whittum-Hudson, JA., & Hudson, AP (2002). Persistent Chlamydiae and 
chronic arthritis. Arthritis Res , Vol.4 , pp. 5–9. 
[66] Virok, D., Kis, Z, Karai, L., et al (2001). Chlamydia pneumoniae in artherosclerotic middle 
cerebral artery. Stroke  , Vol.32, pp.1973–1976. 
[67] Wang C.,  Gao D., Kaltenboeck B (2009). Acute Chlamydia pneumoniae Reinfection 
Accelerates the Development of Insulin Resistance and Diabetes in Obese C57BL/6 
Mice. Journal of Infectious Diseases , Vol. 200, No2 , pp. 279-287. 
[68] Ward ME (1995). The immunobiology and immunopathology of chlamydial infections. 
APMIS, Vol. 103 , pp.769–796. 
[69] Wilkinson, NZ., Kingsley, GH., Sieper, J., Braun, J., & Ward, ME (1998). Lack of 
correlation between the detection of Chlamydia trachomatis DNA in synovial fluid 
from patients with a range of rheumatic diseases and the presence of an 
antichlamydial immune response. Arthritis Rheum ,  Vol.41, No.5, pp.845-54 
[70] Wimmer, ML, Scandmann-Strupp, R, Saiku, P, & Haberl, RL (1996). Association of 
chlamydial  infection with cardiovascular diseases. Strok   , Vol. 27, pp. 2207-2210. 
[71] Woodruff, JF (1980). Viral myocarditis. A review. Am J Pathol   , Vol.101, pp.425-84. 
[72] Wozniak, MA., Cookson, A., Wilcock, GK., & Itzhaki, RF (2003). Absence of Chlamydia 
pneumoniae in brain of vascular dementia patients. Neurobiol Aging , Vol.24 , 
pp.761–765. 
[73] xu, H., Barnes, GT., Yang, Q., et al (2003). Chronic inflammation in fat plays a crucial 
role in the development of obesity-related insulin resistance. J Clin Invest , Vol.112 
,pp.1821-30 
[74] Yao, S-Y.,&  Sriram S (1999). Reactivity of oligoclonal bands seen in CSF to C. 
pneumoniae antigens in patients with multiple sclerosis. Neurology , Vol. 52 (Suppl 2) 
,pp. A559. 
www.intechopen.com
 
Chlamydia 304 
[75] Yasojima, K., Schwab, C., McGeer, EG., & McGeer, PL (2000). Human neurons generate 
C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res, 
Vol.887 , pp.80–89.   
www.intechopen.com
Chlamydia
Edited by Prof. Mihai Mares
ISBN 978-953-51-0470-4
Hard cover, 358 pages
Publisher Intech
Published online 30, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Nowadays, Chlamydia still represents a redoubtable pathogen. Among its consequences, the blindness in
children and severe impairment of reproductive health in adults are the most mutilating. Worldwide, it is
estimated that six million of people suffer from post-trachoma blindness and almost 90 million become sexually
infected each year. Due to its silent evolution and sexually transmission, the chlamydial infection can occur in
anyone. The book “Chlamydia - A Multifaceted Pathogen” contains an updated review of all-important issues
concerning the chlamydial infection. It comprises 18 chapters grouped in four major parts dealing with etiology
and pathogenicity, clinical aspects, diagnosis and prevention. The new molecular data about the pathogenicity
and the exhaustive presentation of clinical findings bring novelty to the book and improve our knowledge about
Chlamydia induced diseases.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Hamidreza Honarmand (2012). Pathogenesis of Chlamydia pneumonia Persistent Illnesses in Autoimmune
Diseases, Chlamydia, Prof. Mihai Mares (Ed.), ISBN: 978-953-51-0470-4, InTech, Available from:
http://www.intechopen.com/books/chlamydia/chlamydia-pneumoniae-and-autoimmune-diseases
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
